STOCK TITAN
  1. Home
  2. News
  3. DGX

Quest Diagnostics, Inc. - DGX STOCK NEWS

Welcome to our dedicated news page for Quest Diagnostics (Ticker: DGX), a resource for investors and traders seeking the latest updates and insights on Quest Diagnostics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quest Diagnostics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quest Diagnostics's position in the market.

News
Quest Diagnostics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Guidance for Full Year 2024; Increases Quarterly Dividend 5.6% to $0.75 Per Share
Rhea-AI Summary
Quest Diagnostics (DGX) reported a 1.9% decrease in fourth quarter revenues, with a 95.4% increase in reported diluted EPS and an 8.6% increase in adjusted diluted EPS. Full year revenues were down 6.4% from 2022, with reported diluted EPS down 6.0% and adjusted diluted EPS down 12.5%. The company expects full year 2024 reported diluted EPS to be between $7.69 and $7.99, and adjusted diluted EPS to be between $8.60 and $8.90. Quest Diagnostics' Board of Directors has authorized a 5.6% increase in its quarterly dividend. The company estimates full year 2024 guidance with a net revenues increase of 1.1% to 2.1%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
dividends earnings
-
News
Ten Years Running: FORTUNE Names Quest Diagnostics one of 2024 "World's Most Admired Companies"
Rhea-AI Summary
Quest Diagnostics (NYSE: DGX) has been recognized as one of FORTUNE's World's Most Admired Companies in 2024 for the tenth consecutive year. The company scored high marks in people management, use of corporate assets, and social responsibility, making it one of only five companies to attain Most Admired status in the 'Health Care: Pharmacy and Other Services' industry. The recognition is based on nine criteria of corporate reputation, including innovation, quality of management and products, and social responsibility. Quest Diagnostics' Chairman, CEO, and President, Jim Davis, expressed gratitude to the company's dedicated colleagues for their role in achieving this honor.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.31%
Tags
none
-
News
Fitbit and Quest Diagnostics Collaborate To Advance Research on the Use of Wearable Devices To Improve Metabolic Health
Rhea-AI Summary
Fitbit and Quest Diagnostics (NYSE:DGX) have announced a collaboration to study the potential of wearable devices to improve metabolic health, aiming to evaluate the effect of wearables on users' behaviors based on objective laboratory test results. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways data can be combined and analyzed to improve the assessment and management of metabolic health and help to inform the prevention of disease. The study will invite approximately 1,500 existing Fitbit users to join and consent to share three months of their Fitbit data and receive laboratory testing at no cost using a panel of blood tests specifically designed to assess metabolic health. This study is expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
News
Haystack Oncology, developer of Haystack MRD™, and TriSalus Life Sciences collaborate in connection with the clinical development of TriSalus' TLR9 agonist in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and pancreatic adenocarcinoma
Rhea-AI Summary
Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist. The collaboration aims to overcome challenges associated with treating liver and pancreatic tumors by utilizing Haystack MRD™ technology to accurately detect circulating tumor DNA (ctDNA) with unparalleled sensitivity in patients with low tumor burden and in clinically challenging cancer types. The partnership is focused on supporting the clinical development of SD-101 in combination with TriSalus' unique therapy delivery technology, Pressure-Enabled Drug Delivery™ (PEDD™). This collaboration has the potential to offer better therapeutic options for patients with liver and pancreatic tumors, addressing significant challenges in the development of immunotherapies for these cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.4%
Tags
clinical trial
-
News
Quest Diagnostics to Release Fourth Quarter and Full Year 2023 Financial Results on February 1, 2024
Rhea-AI Summary
Quest Diagnostics (DGX) will report Q4 and full year 2023 financial results on February 1, 2024. The company will hold a conference call to discuss the results and provide access to a live webcast. Participants can access the call and webcast via dial-in or online replay. The company encourages participants to read its periodic reports on file with the SEC, including risk factors and historical results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
earnings
-
News
Fitbit and Quest Diagnostics Collaborate to Advance Research on the Use of Wearable Devices to Improve Metabolic Health
Rhea-AI Summary
Fitbit and Quest Diagnostics (NYSE: DGX) have announced a collaboration to study the potential of wearable devices to improve metabolic health, aiming to assess and manage metabolic health to prevent diseases like diabetes and heart disease. The Wearables for Metabolic Health (WEAR-ME) pilot study will pair behavioral and biometric data from Fitbit devices with health insights from Quest Diagnostics' laboratory tests to explore ways data can be combined and analyzed to improve health outcomes. The study will invite 1,500 Fitbit users to join and consent to share three months of their Fitbit data, as well as receive laboratory testing at no cost using a panel of blood tests specifically designed to assess metabolic health. The study is expected to be completed in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
News
Quest Diagnostics and Ultima Collaborate to Scale Ultima’s Technology in Fast-Growing Minimal Residual Disease and Whole Genome Sequencing
Rhea-AI Summary
Ultima Genomics (UG) and Quest Diagnostics (DGX) collaborate to improve patient access, affordability, and outcomes through the use of Ultima's next generation sequencing (NGS) technology in oncology and other clinical areas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
News
Quest Diagnostics Acquires Select Assets of Outreach Lab Services Business of Steward Health Care System
Rhea-AI Summary
Quest Diagnostics (DGX) acquires select assets of Steward Health Care System's outreach laboratory services business in Pennsylvania and Ohio to broaden access to innovative, quality, and cost-effective laboratory services. The financial details of the transaction were not disclosed. The acquisition aims to serve the evolving needs of health systems and aligns with Quest's strategy to grow through accretive outreach laboratory acquisitions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
acquisition
-
News
Haystack Oncology and Alliance Foundation Trials collaborate to use Haystack MRD™ technology in phase II clinical trial for unresectable stage III NSCLC
Rhea-AI Summary
Haystack Oncology (DGX) collaborates with Alliance Foundation Trials, LLC (AFT) to utilize its personalized MRD technology (Haystack MRD™) in AFT-57 clinical trial for unresectable stage III non-small cell lung cancer. The study, supported by Genentech, will evaluate the efficacy and safety of atezolizumab with or without tiragolumab in conjunction with chemoradiotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.27%
Tags
clinical trial
News
No-Cost Testing Helps Bolster I-HEAL Community Wellness Day in Mississippi Delta Region
Rhea-AI Summary
Quest Diagnostics (ticker symbol: QD) provided no-cost Blueprint for Wellness® testing to over 100 local community members at the ninth annual I-HEAL Community Wellness Day in the Mississippi Delta region. The event, hosted by Quest for Health Equity (Q4HE) grantee Glenn Family Foundation, offered health screenings, nutritious food, mental health resources, vaccines, cleaning supplies, and diapers. Blueprint for Wellness offers comprehensive health screenings to empower individuals with personalized health insights.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
Stock DGX logo
Quest Diagnostics, Inc.

NYSE:DGX

DGX Rankings

#641 Ranked by Market Cap
#2771 Ranked by Stock Gains
#1308 Ranked by Dividends

DGX Stock Data

14.27B
109.71M
0.43%
91.73%
2.29%
Medical Laboratories
Health Care and Social Assistance
Link
US
Secaucus

About DGX

quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator